Opinion|Videos|December 2, 2024
Malignancy Risks of Neurokinin Receptor Antagonists
Panelists discuss clinical trial data suggesting a small but higher incidence of endometrial hyperplasia or malignancy with fezolinetant, while no cases of endometrial hyperplasia or malignancy were observed with elinzanetant in a long-term safety study.
Advertisement
Episodes in this series
What does data from the clinical trials suggest about the incidence of neoplasms with fezolinetant and elinzanetant?
Notes:Across 3 clinical trials, fezolinetant is associated with a small, but higher incidence of endometrial hyperplasia or endometrial malignancy.
There were no cases of endometrial hyperplasia or endometrial malignancy observed with elinzanetant in a long-term safety study.
Advertisement
Related to this article
This FAQ summarizes a Special Report discussion on how two experts decide who is a candidate for testosterone therapy in women, from symptoms and context to hormone state vs age.
This FAQ summarizes a Special Report discussion of what the evidence does and does not establish about testosterone therapy in women.
Kanchi Chadha, MD, FACOG, MSCP, supports reconsidering MHT boxed warnings but says the FDA cited no study behind the change.
HRSA will award up to $1 million to a single organization to update the Women's Preventive Services Guidelines through the new WISH program.
Real-world data show maternal RSVpreF vaccination was 82% effective against infant RSV LRTI hospitalization through 3 months.
Soma Mandal, MD, MSCP, says removing MHT boxed warnings is overdue but calls for transparency on the FDA's product-specific rationale.
CMS' proposed G-codes, which experts stated would cause confusion in combination with the AMA's proposed codes, were not included in the final fee schedule for 2027, according to ACOG.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Top video interviews from The Menopause Society 2026 Annual Meeting
2
Centers for Medicare, Medicaid Services includes AMA's obstetric codes in 2027 fee schedule
3
Q&A: Peter Hsin, BS, on perioperative ketamine and early postpartum depression
4
FAQ: Who is a candidate for testosterone therapy in women?
5